LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article: Raloxifene impedes cisplatin-induced nephrotoxicity through inhibition of Proinflammatory cytokines in female wistar rats.

    Li, Hongying / Jamdade, Vinayak S

    Pakistan journal of pharmaceutical sciences

    2022  Volume 34, Issue 6, Page(s) 2141–2147

    Abstract: Cisplatin mediated nephrotoxicity is the main obstacle in the practice of cisplatin as a chemotherapeutic agent. Conversely, it continues to be the most commonly used anticancer agent to treat several solid tumours. This study investigated the effect of ... ...

    Abstract Cisplatin mediated nephrotoxicity is the main obstacle in the practice of cisplatin as a chemotherapeutic agent. Conversely, it continues to be the most commonly used anticancer agent to treat several solid tumours. This study investigated the effect of raloxifene pretreatment on nephrotoxicity mediated by cisplatin in an experimental animal model. The levels of blood urea nitrogen, creatinine, and albumin were measured to evaluate the renal damage, and the levels of proinflammatory cytokines such as interleukin 6 (IL-6), interleukin 10 (IL-10), and tumour necrosis factor-alpha (TNF-α) were measured to assess the systemic inflammation. Cisplatin in a single dose of 7.5mg/kg showed a substantial rise in serum levels of blood urea nitrogen, creatinine along with TNF-α and IL-6 and, fall in albumin and IL-10 levels. Nevertheless, there was no substantial change in a group treated with raloxifene 7.5mg/kg. We observed a substantial fall in the levels of blood urea nitrogen, creatinine along with TNF-α and IL-6 and a rise in albumin and IL-10 levels. The current study established a protective effect of raloxifene in cisplatin mediated nephrotoxicity and this is due to its potential anti-oxidant and anti-inflammatory properties. Therefore, a cisplatin induced nephrotoxicity can be prevented by the use of raloxifene as a therapeutic adjuvant.
    MeSH term(s) Animals ; Anti-Inflammatory Agents/pharmacology ; Blood Urea Nitrogen ; Cisplatin ; Creatinine/blood ; Cytokines/blood ; Disease Models, Animal ; Female ; Inflammation Mediators/blood ; Kidney/drug effects ; Kidney/metabolism ; Kidney/pathology ; Kidney Diseases/blood ; Kidney Diseases/chemically induced ; Kidney Diseases/pathology ; Kidney Diseases/prevention & control ; Raloxifene Hydrochloride/pharmacology ; Rats, Wistar ; Rats
    Chemical Substances Anti-Inflammatory Agents ; Cytokines ; Inflammation Mediators ; Raloxifene Hydrochloride (4F86W47BR6) ; Creatinine (AYI8EX34EU) ; Cisplatin (Q20Q21Q62J)
    Language English
    Publishing date 2022-01-11
    Publishing country Pakistan
    Document type Journal Article
    ZDB-ID 885131-1
    ISSN 1011-601X
    ISSN 1011-601X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6588: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Clinical, Economic, and Patient-Reported Benefits of Connected Insulin Pen Systems: A Systematic Literature Review.

    Cranston, Iain / Jamdade, Vinayak / Liao, Birong / Newson, Rachel S

    Advances in therapy

    2023  Volume 40, Issue 5, Page(s) 2015–2037

    Abstract: Introduction: The objective of this systematic literature review was to evaluate the available literature concerning the clinical, economic, and patient-reported benefits of insulin pen platforms, including connected insulin pens/caps/sleeves and ... ...

    Abstract Introduction: The objective of this systematic literature review was to evaluate the available literature concerning the clinical, economic, and patient-reported benefits of insulin pen platforms, including connected insulin pens/caps/sleeves and insulin platforms, as well as mobile apps capable of receiving near real-time insulin dosing information.
    Methods: Medline and Embase databases and the Cochrane Library were searched for published literature between January 2015 and May 2021, and manual searches for conference abstracts from 2018 to May 2021 were performed. These searches were supplemented by internet searches for relevant literature and clinical trials. Study selection involved the population, intervention, comparator, outcomes, time frame, and study design outline. Included studies investigated connected insulin systems or connected caps/sleeves enabling pens to be connected, or apps able to connect to these systems, in individuals of all ages with type 1 or type 2 diabetes mellitus.
    Results: Searches identified a total of 26 publications (mostly observational studies and conference abstracts) for inclusion, representing ten unique, predominantly small studies. Evidence in this field is still in its early stages, and only two randomized controlled trials met our inclusion criteria. Available results showed that connected insulin pens and their systems potentially helped reduce suboptimal insulin use and may therefore improve glycemic control. Satisfaction of people with diabetes with the technologies used was high, and economic benefits were noted. Features of effective connected insulin pen devices include simplicity of use and data upload/sharing, useful "point-of-care" alerts, and simple and understandable data presentation to facilitate more effective consultations.
    Conclusions: Connected insulin pen systems could be increasingly considered as part of routine clinical care for insulin-treated persons with diabetes who must manage the complexity of their daily insulin routine. Future research focusing on the way data obtained from these devices can be most effectively used alongside other information is urgently needed.
    MeSH term(s) Humans ; Diabetes Mellitus, Type 1/drug therapy ; Diabetes Mellitus, Type 2/drug therapy ; Randomized Controlled Trials as Topic ; Insulin/administration & dosage ; Insulin/economics ; Hypoglycemic Agents/administration & dosage ; Hypoglycemic Agents/economics ; Mobile Applications ; Point-of-Care Systems ; Injections, Subcutaneous ; Cost-Benefit Analysis
    Chemical Substances Insulin ; Hypoglycemic Agents
    Language English
    Publishing date 2023-03-16
    Publishing country United States
    Document type Journal Article ; Systematic Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 632651-1
    ISSN 1865-8652 ; 0741-238X
    ISSN (online) 1865-8652
    ISSN 0741-238X
    DOI 10.1007/s12325-023-02478-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2101: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Therapeutic targets of triple-negative breast cancer: a review.

    Jamdade, Vinayak S / Sethi, Nikunj / Mundhe, Nitin A / Kumar, Parveen / Lahkar, Mangala / Sinha, Neeraj

    British journal of pharmacology

    2015  Volume 172, Issue 17, Page(s) 4228–4237

    Abstract: Breast cancer (BC) is the second most common cause of cancer deaths. Triple-negative breast cancer (TNBC) does not show immunohistochemical expression of oestrogen receptors, progesterone receptors or HER2. At present, no suitable treatment option is ... ...

    Abstract Breast cancer (BC) is the second most common cause of cancer deaths. Triple-negative breast cancer (TNBC) does not show immunohistochemical expression of oestrogen receptors, progesterone receptors or HER2. At present, no suitable treatment option is available for patients with TNBC. This dearth of effective conventional therapies for the treatment of advanced stage breast cancer has provoked the development of novel strategies for the management of patients with TNBC. This review presents recent information associated with different therapeutic options for the treatment of TNBC focusing on promising targets such as the Notch signalling, Wnt/β-catenin and Hedgehog pathways, in addition to EGFR, PARP1, mTOR, TGF-β and angiogenesis inhibitors.
    MeSH term(s) Animals ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/metabolism ; Drug Delivery Systems/methods ; Drug Delivery Systems/trends ; Female ; Hedgehog Proteins/metabolism ; Humans ; Molecular Targeted Therapy/methods ; Molecular Targeted Therapy/trends ; Receptor, ErbB-2/metabolism ; Receptors, Estrogen/metabolism ; Receptors, Notch/metabolism ; Signal Transduction/drug effects ; Signal Transduction/physiology ; Triple Negative Breast Neoplasms/drug therapy ; Triple Negative Breast Neoplasms/metabolism
    Chemical Substances Antineoplastic Agents ; Hedgehog Proteins ; Receptors, Estrogen ; Receptors, Notch ; Receptor, ErbB-2 (EC 2.7.10.1)
    Language English
    Publishing date 2015-09
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 80081-8
    ISSN 1476-5381 ; 0007-1188
    ISSN (online) 1476-5381
    ISSN 0007-1188
    DOI 10.1111/bph.13211
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uf I Zs.146: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Statin use and the risk of developing diabetes: a network meta-analysis.

    Thakker, Divyesh / Nair, Sunita / Pagada, Amit / Jamdade, Vinayak / Malik, Anuradha

    Pharmacoepidemiology and drug safety

    2016  Volume 25, Issue 10, Page(s) 1131–1149

    Abstract: Purpose: Randomized controlled trials have shown mixed findings regarding the association of statins and diabetes. This systematic literature review and network meta-analysis (NMA) was performed to update evidence on this association to possibly assist ... ...

    Abstract Purpose: Randomized controlled trials have shown mixed findings regarding the association of statins and diabetes. This systematic literature review and network meta-analysis (NMA) was performed to update evidence on this association to possibly assist clinicians in making more informed treatment choices.
    Methods: We identified studies relevant to our NMA by performing study searches in databases like Embase, Cochrane, and PubMed, published between August 2010 and June 2014. Pre-2010 studies were identified from bibliography of previously published meta-analyses. Unpublished study data were found from clinicaltrial.gov. Data synthesis was performed by pairwise meta-analysis and NMA within a Frequentist framework.
    Results: Twenty nine trials in which 1 63 039 participants had been randomized were included in this review; among these 1 41 863 were non-diabetic patients. The direct meta-analysis showed that statins, as a class, significantly increased the likelihood of developing diabetes by 12% (pooled OR 1.12; 95%CI 1.05-1.21; I
    Conclusions: Based on the results, statins, as a class, increased the risk of diabetes significantly in the pairwise meta-analysis. Overall, there appears to be a small increased risk of incident diabetes, particularly with more intensive statin therapy, although more data would be valuable to increase the robustness of this interpretation, given that the lower confidence intervals of our study analyses are close to, or just crossing one. Copyright © 2016 John Wiley & Sons, Ltd.
    MeSH term(s) Confidence Intervals ; Diabetes Mellitus, Type 2/epidemiology ; Diabetes Mellitus, Type 2/etiology ; Dose-Response Relationship, Drug ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Randomized Controlled Trials as Topic ; Risk
    Chemical Substances Hydroxymethylglutaryl-CoA Reductase Inhibitors
    Language English
    Publishing date 2016-06-09
    Publishing country England
    Document type Comparative Study ; Journal Article ; Meta-Analysis ; Review ; Systematic Review
    ZDB-ID 1099748-9
    ISSN 1099-1557 ; 1053-8569
    ISSN (online) 1099-1557
    ISSN 1053-8569
    DOI 10.1002/pds.4020
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3395: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Role of toll-like receptors in multiple myeloma and recent advances.

    Thakur, Krishan K / Bolshette, Nityanand B / Trandafir, Cristiana / Jamdade, Vinayak S / Istrate, Alexandru / Gogoi, Ranadeep / Cucuianu, Andrei

    Experimental hematology

    2015  Volume 43, Issue 3, Page(s) 158–167

    Abstract: Multiple myeloma (MM) is a hematologic malignancy characterized as an abnormal proliferation and invasion of plasma cells into the bone marrow. Toll-like receptors (ТLRs) connect the innate and adaptive immune responses and represent a significant and ... ...

    Abstract Multiple myeloma (MM) is a hematologic malignancy characterized as an abnormal proliferation and invasion of plasma cells into the bone marrow. Toll-like receptors (ТLRs) connect the innate and adaptive immune responses and represent a significant and potentially linking element between inflammation and cancer. When TLRs bind to their ligands, they trigger two major signaling pathways such that both share overlapping downstream signals: one is a myeloid differentiation primary response 88 (MyD88)-dependent production and activation of nuclear factor-κB, whereas the other is a MyD88-independent production of type-I interferon. Whereas the MyD88 pathway results in proinflammatory cytokine production, the other pathway stimulates cell proliferation. Dysregulations of these pathways may eventually lead to abnormal cell proliferation and MM. Despite recent biomedical advances, MM continues to be an incurable disease. There are an increasing number of TLR-based therapeutic approaches currently being tested in a number of preclinical and clinical studies. We here attempt to outline in detail the currently available information on TLRs in various types of cancer.
    MeSH term(s) Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Drug Delivery Systems/trends ; Humans ; Multiple Myeloma/drug therapy ; Multiple Myeloma/physiopathology ; Signal Transduction/drug effects ; Toll-Like Receptors/metabolism
    Chemical Substances Antineoplastic Agents ; Toll-Like Receptors
    Language English
    Publishing date 2015-03
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 185107-x
    ISSN 1873-2399 ; 0531-5573 ; 0301-472X
    ISSN (online) 1873-2399
    ISSN 0531-5573 ; 0301-472X
    DOI 10.1016/j.exphem.2014.11.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 922: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Nordihydroguaiaretic acid ameliorates cisplatin induced nephrotoxicity and potentiates its anti-tumor activity in DMBA induced breast cancer in female Sprague-Dawley rats.

    Mundhe, Nitin Arunrao / Kumar, Parveen / Ahmed, Sahabuddin / Jamdade, Vinayak / Mundhe, Sanjay / Lahkar, Mangala

    International immunopharmacology

    2015  Volume 28, Issue 1, Page(s) 634–642

    Abstract: Cisplatin is a widely used antineoplastic drug, but its clinical usefulness is limited due to dose dependent nephrotoxicity. Nordihydroguaiaretic acid (NDGA) is a natural compound with broad pharmacological properties like antioxidant, anti-inflammatory ... ...

    Abstract Cisplatin is a widely used antineoplastic drug, but its clinical usefulness is limited due to dose dependent nephrotoxicity. Nordihydroguaiaretic acid (NDGA) is a natural compound with broad pharmacological properties like antioxidant, anti-inflammatory and anticancer activity. The present study was undertaken to evaluate the possible beneficial effects of NDGA on cisplatin induced nephrotoxicity as well as its anticancer activity in rats bearing DMBA induced mammary tumors. The effect of NDGA on cisplatin induced nephrotoxicity was evaluated by checking serum nephrotoxicity markers, antioxidant enzymes and inflammatory markers level and kidney histopathology. NDGA induced amelioration of cisplatin nephrotoxicity was clearly visible from significant reductions in serum blood urea nitrogen (86.51 g/dl) and creatinine (5.30 g/dl) levels and significant improvement in body weight change (-10.34 g) and kidney weight (728 mg/kg). The protective effect of NDGA against cisplatin induced nephrotoxicity in the rats was further confirmed by significant restoration of antioxidant enzymes like SOD (86.28% inhibition), inflammatory markers like TNF-α (34.6 pg/ml) and histopathological examination. Moreover, our results showed that NDGA potentiated anti-breast cancer activity of cisplatin through an increment in the expression of antioxidant enzymes like SOD (85.35% inhibition) in breast cancer tissue. These results indicated that NDGA potentiated the anti-breast cancer activity of cisplatin, which was clearly evident from the tumor volume and % tumor inhibition in breast cancer rats. The current study demonstrated that NDGA may modify the therapeutic effect of cisplatin in DMBA induced breast cancer in female Sprague-Dawley rats.
    MeSH term(s) 9,10-Dimethyl-1,2-benzanthracene/pharmacology ; Animals ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Antioxidants/administration & dosage ; Antioxidants/therapeutic use ; Blood Urea Nitrogen ; Catalase/metabolism ; Cisplatin/administration & dosage ; Cisplatin/adverse effects ; Cisplatin/therapeutic use ; Creatinine/blood ; Female ; Kidney/drug effects ; Kidney/pathology ; Kidney Diseases/chemically induced ; Kidney Diseases/metabolism ; Kidney Diseases/pathology ; Kidney Diseases/prevention & control ; Lipid Peroxidation/drug effects ; Mammary Neoplasms, Experimental/chemically induced ; Mammary Neoplasms, Experimental/drug therapy ; Mammary Neoplasms, Experimental/pathology ; Masoprocol/administration & dosage ; Masoprocol/therapeutic use ; Rats, Sprague-Dawley ; Superoxide Dismutase/metabolism ; Tumor Burden/drug effects
    Chemical Substances Antineoplastic Agents ; Antioxidants ; 9,10-Dimethyl-1,2-benzanthracene (57-97-6) ; Masoprocol (7BO8G1BYQU) ; Creatinine (AYI8EX34EU) ; Catalase (EC 1.11.1.6) ; Superoxide Dismutase (EC 1.15.1.1) ; Cisplatin (Q20Q21Q62J)
    Language English
    Publishing date 2015-09
    Publishing country Netherlands
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2043785-7
    ISSN 1878-1705 ; 1567-5769
    ISSN (online) 1878-1705
    ISSN 1567-5769
    DOI 10.1016/j.intimp.2015.07.016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5408: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top